Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy

About 70–80% of early breast cancer (BC) patients receive adjuvant endocrine therapy (ET) for at least 5 years. ET includes in the majority of cases the use of aromatase inhibitors, as upfront or switch strategy, that lead to impaired bone health. Given the high incidence and also the high prevalenc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Curr Treat Options Oncol
Main Authors: Diana, Anna, Carlino, Francesca, Giunta, Emilio Francesco, Franzese, Elisena, Guerrera, Luigi Pio, Di Lauro, Vincenzo, Ciardiello, Fortunato, Daniele, Bruno, Orditura, Michele
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2021
Assuntos:
Breast Cancer (WJ Gradishar, Section Editor)
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8052225/
https://ncbi.nlm.nih.gov/pubmed/33864145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-021-00835-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados